Mainz Biomed Future Growth
Future criteria checks 2/6
Mainz Biomed is forecast to grow earnings and revenue by 1.2% and 53.9% per annum respectively while EPS is expected to grow by 44.4% per annum.
Key information
1.2%
Earnings growth rate
44.4%
EPS growth rate
| Biotechs earnings growth | 24.2% |
| Revenue growth rate | 53.9% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Jun 2024 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 13 | -41 | -54 | -49 | 2 |
| 12/31/2025 | 4 | -46 | -65 | -60 | 2 |
| 12/31/2024 | 1 | -34 | -49 | -45 | 3 |
| 12/31/2023 | 1 | -26 | -24 | -22 | N/A |
| 9/30/2023 | 1 | -29 | -24 | -22 | N/A |
| 6/30/2023 | 1 | -29 | -21 | -19 | N/A |
| 3/31/2023 | 1 | -27 | -20 | -18 | N/A |
| 12/31/2022 | 1 | -26 | -15 | -15 | N/A |
| 9/30/2022 | 0 | -24 | -12 | -12 | N/A |
| 6/30/2022 | 0 | -24 | -10 | -10 | N/A |
| 3/31/2022 | 1 | -17 | -6 | -6 | N/A |
| 12/31/2021 | 1 | -12 | -3 | -3 | N/A |
| 12/31/2020 | 0 | -1 | 0 | 0 | N/A |
| 12/31/2019 | 0 | -1 | 0 | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYNZ is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MYNZ is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MYNZ is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MYNZ's revenue (53.9% per year) is forecast to grow faster than the US market (8.7% per year).
High Growth Revenue: MYNZ's revenue (53.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MYNZ's Return on Equity is forecast to be high in 3 years time